February 11, 2026-
Fourth Quarter Highlights
- Total revenues increased to $105.7 billion, up 8.2% compared to prior year
- GAAP diluted EPS of $2.30 and Adjusted EPS of $1.09
Full-Year Highlights
- Total revenues increased to a record high $402.1 billion, up 7.8% compared to prior year
- GAAP diluted EPS of $1.39 and Adjusted EPS of $6.75
- Generated cash flow from operations of $10.6 billion
Operational Highlights
- CVS Pharmacy® successfully completed the transition to cost-based reimbursement across its Commercial, Third-Party Discount, Medicare and Medicaid businesses.
- Aetna® continues to improve the experience for health care professionals and their patients, approving more than 95% of all eligible prior authorizations within 24 hours, with many completed instantaneously.
- Caremark® closes out 2025 with significant customer wins and strong retention, providing momentum into 2026.
2026 Full-Year Guidance
- Updated cash flow from operations guidance to at least $9.0 billion from at least $10.0 billion
- Confirmed GAAP diluted EPS guidance range of $5.94 to $6.14
- Confirmed Adjusted EPS guidance range of $7.00 to $7.20